Pfizer Company Profile (NYSE:PFE)

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:PFE
  • CUSIP: 71708110
  • Web:
  • Market Cap: $191.81 billion
  • Outstanding Shares: 5,967,844,000
Average Prices:
  • 50 Day Moving Avg: $33.30
  • 200 Day Moving Avg: $32.94
  • 52 Week Range: $29.83 - $37.39
  • Trailing P/E Ratio: 27.05
  • Foreward P/E Ratio: 11.73
  • P/E Growth: 2.24
Sales & Book Value:
  • Annual Revenue: $52.6 billion
  • Price / Sales: 3.65
  • Book Value: $9.79 per share
  • Price / Book: 3.28
  • Annual Dividend: $1.28
  • Dividend Yield: 4.0%
  • EBIDTA: $19.51 billion
  • Net Margins: 13.50%
  • Return on Equity: 23.18%
  • Return on Assets: 8.60%
  • Debt-to-Equity Ratio: 0.48%
  • Current Ratio: 1.11%
  • Quick Ratio: 0.89%
  • Average Volume: 21.94 million shs.
  • Beta: 0.94
  • Short Ratio: 3.45

Frequently Asked Questions for Pfizer (NYSE:PFE)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Friday, April 28th. Stockholders of record on Friday, May 12th will be given a dividend of $0.32 per share on Thursday, June 1st. This represents a $1.28 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Wednesday, May 10th. View Pfizer's Dividend History.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The firm's quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 EPS. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $2.50-2.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.55. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $53.15 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

18 brokerages have issued 1 year price targets for Pfizer's stock. Their predictions range from $31.00 to $53.00. On average, they anticipate Pfizer's share price to reach $37.88 in the next year. View Analyst Ratings for Pfizer.

What are analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 2. According to Zacks Investment Research, "Pfizer has been working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. While the Hospira acquisition significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal strengthened its cancer franchise by adding Xtandi to its portfolio. Pfizer’s new products like Ibrance should do well and drive revenues in 2017 while cost-savings and share buybacks should boost earnings. Pfizer’s shares surpassed that of large-cap pharma industry in the past one year. The company has a positive record of earnings surprises in recent quarters. Investor focus will remain on the stock as Pfizer has several key pipeline milestones in 2017. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. Estimates have declined slightly ahead of its Q4 earnings release." (1/25/2017)
  • 3. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 46,876,487 shares, an increase of 1.0% from the April 28th total of 47,334,456 shares. Based on an average daily trading volume, of 24,677,510 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.8% of the shares of the stock are short sold.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations
  • Albert Bourla, Group President - Pfizer Innovative Health
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development
  • John D. Young, Group President - Pfizer Essential Health
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer
  • Douglas M. Lankler, Executive Vice President, General Counsel
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer
  • Kirsten Lund-Jurgensen, Executive Vice President, President - Pfizer Global Supply

Who owns Pfizer stock?

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.50%), Vanguard Group Inc. (6.88%), State Street Corp (5.37%), Wellington Management Group LLP (1.23%), Bank of New York Mellon Corp (1.18%) and State Farm Mutual Automobile Insurance Co. (1.00%). Company insiders that own Pfizer stock include Albert Bourla, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., APG Asset Management N.V., Parametric Portfolio Associates LLC, Canada Pension Plan Investment Board, Lazard Asset Management LLC, Ameriprise Financial Inc., Caisse DE Depot ET Placement DU Quebec and PNC Financial Services Group Inc.. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Anthony J Maddaluna, Charles H Hill, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Cibc World Markets Corp, Vanguard Group Inc., Swiss National Bank, Wellington Management Group LLP, Morgan Stanley and Geode Capital Management LLC. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $32.14.

MarketBeat Community Rating for Pfizer (NYSE PFE)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  744 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  1,071
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pfizer (NYSE:PFE) (?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $37.88 (17.84% upside)

Analysts' Ratings History for Pfizer (NYSE:PFE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Citigroup IncDowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
5/3/2017Barclays PLCReiterated RatingBuy$38.00LowView Rating Details
5/3/2017Sanford C. BernsteinReiterated RatingBuy$37.00LowView Rating Details
4/27/2017BMO Capital MarketsReiterated RatingHold$33.00LowView Rating Details
4/13/2017Jefferies Group LLCReiterated RatingNeutral$34.00 -> $35.00LowView Rating Details
4/6/2017Morgan StanleyReiterated RatingNeutral$38.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
3/13/2017Credit Suisse Group AGSet Price TargetBuy$38.00LowView Rating Details
2/17/2017Berenberg BankSet Price TargetNeutral$39.00N/AView Rating Details
2/16/2017Deutsche Bank AGReiterated RatingBuy$40.00N/AView Rating Details
2/2/2017Morningstar, Inc.Reiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
1/18/2017Goldman Sachs Group IncSet Price TargetNeutral$36.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of America CorpReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
8/3/2016JPMorgan Chase & Co.Set Price TargetBuy$40.00N/AView Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust Banks, Inc.Lower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
1/26/2016Nord/LBReiterated RatingBuyN/AView Rating Details
12/2/2015Cowen and CompanyReiterated RatingBuy$43.00N/AView Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 5/30/2015 forward)


Earnings History for Pfizer (NYSE:PFE)
Earnings by Quarter for Pfizer (NYSE:PFE)
Earnings History by Quarter for Pfizer (NYSE PFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfizer (NYSE:PFE)
2017 EPS Consensus Estimate: $2.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.67$0.67$0.67
Q2 20172$0.62$0.66$0.64
Q3 20172$0.63$0.64$0.64
Q4 20172$0.56$0.60$0.58
(Data provided by Zacks Investment Research)


Current Dividend Information for Pfizer (NYSE:PFE)
Next Dividend:6/1/2017
Annual Dividend:$1.28
Dividend Yield:3.98%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:110.35% (Trailing 12 Months of Earnings)
50.20% (Based on This Year's Estimates)
46.72% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Dividend History by Quarter for Pfizer (NYSE PFE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pfizer (NYSE:PFE)
Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 69.53%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.00View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.00View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.70View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pfizer (NYSE:PFE)
Latest Headlines for Pfizer (NYSE:PFE)
DateHeadline logoPfizer Inc. (PFE) Receives Average Rating of "Hold" from Brokerages - May 30 at 12:39 AM logo3 Top Dividend Stocks in Cancer Drugs - May 28 at 11:34 AM logoPfizer's Epogen Biosimilar Gets Positive FDA Committee Vote - May 26 at 8:40 PM logoAre Regeneron, Sanofi Treading On Pfizer In Eczema? - May 26 at 8:40 PM logo3 Top Dividend Stocks in Generic Drugs - May 26 at 3:39 PM logoFDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen ® /Procrit ® Across All Indications - May 26 at 5:55 AM logoPfizer (PFE) Announces FDA AdCom Recommendation for Epogen/Procrit Biosimilar - May 26 at 5:55 AM logoFDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications - May 26 at 5:55 AM logoPFE Crosses Above 4% Yield Territory - May 25 at 5:28 AM logo3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Pfizer Inc. (PFE) and Amgen, Inc. (AMGN) - - May 24 at 7:26 PM logoPfizer Recommends Stockholders To Reject TRC Capital's Mini-tender Offer - May 24 at 10:07 AM logoPfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation - May 24 at 10:07 AM logoMerck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing - May 23 at 9:55 AM logo3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Pfizer Inc. (PFE) and Amgen, Inc. (AMGN) - May 22 at 1:05 PM logo3 Ways Johnson & Johnson's Pharmaceutical Business Plans to Beat the Market - May 21 at 9:15 AM logo3 Stocks to Supplement Your Social Security Income - May 20 at 8:34 AM logoETFs with exposure to Pfizer Inc. : May 19, 2017 - May 19 at 7:45 PM logo[$$] Iterum Therapeutics Lines Up Funding Ahead of Trials - May 19 at 7:45 PM logoPfizer Inc. :PFE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 - May 19 at 11:58 AM logoPfizer Target of Unusually High Options Trading (PFE) - May 19 at 7:04 AM logoNanoString revises guidance after Astellas and Pfizer ax late-stage study of enzalutamide + chemo in TNBC, $10.6M in deferred revs no longer; shares off 2% - May 18 at 1:34 PM logoPfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting - May 18 at 7:13 AM logoPfizer drug from Medivation deal shows promise in breast cancer -study - May 17 at 7:07 PM logoPfizer: There Is No Upside Without M&A - Seeking Alpha - May 17 at 8:37 AM logoToday's Research Reports on Stocks to Watch: BlackBerry and Pfizer - May 17 at 8:37 AM logoPfizer: Is It Time To Sell? - May 16 at 6:54 PM logoUS STOCKS-Wall St flat after S&P, Nasdaq hit record highs - May 16 at 6:54 PM logoDow's Pfizer, Eli Lilly Topple To 3-Month Lows On Downgrades - May 16 at 6:54 PM logoTop Analyst Upgrades and Downgrades: AIG, Exact Sciences, MercadoLibre, Pfizer, Whole Foods, Valero Energy, Yum Brands and More - May 16 at 9:55 AM logoEarly movers: HD, PFE, BABA, DKS, YHOO, F, VOD, FB, JNJ & more - May 16 at 9:55 AM logoYum Brands, Intuitive Surgical Called Buys; Pfizer Cut To Sell - May 16 at 9:55 AM logoUS STOCKS-S&P, Nasdaq hit record highs on gains in tech, consumer staples - May 16 at 9:55 AM logoPfizer Inc. (PFE) Given a $31.00 Price Target at Citigroup Inc - May 16 at 7:42 AM logoPfizer Inc. (PFE) Sees Significant Decrease in Short Interest - May 15 at 7:50 AM logoHere's Why the Best Is Yet to Come for Pfizer Inc. - May 14 at 6:49 PM logoHere's Why the Best Is Yet to Come for Pfizer Inc. - May 14 at 11:43 AM logoPFE Named 'Top Dividend Stock of the Dow' at Dividend Channel With 3.9% Yield - May 12 at 7:56 PM logoSunTrust Banks Weighs in on Pfizer Inc.'s FY2020 Earnings (PFE) - May 12 at 6:56 PM logo$13.02 Billion in Sales Expected for Pfizer Inc. (PFE) This Quarter - May 12 at 3:44 PM logoWhy Sangamo Therapeutics Is Surging - May 11 at 7:39 PM logoHere's Why Sangamo Therapeutics Rocketed Up to 56.3% Higher Today - May 11 at 1:17 PM logoSunTrust Banks Comments on Pfizer Inc.'s Q2 2017 Earnings (PFE) - May 11 at 7:54 AM logoPfizer strikes deal with Sangamo, broadening hemophilia pipeline - May 11 at 12:27 AM logoRoche's star cancer drug stumbles in study, raising doubts about future - May 11 at 12:27 AM logoPfizer Inc. : PFE-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017 - May 11 at 12:27 AM logoSangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy - May 11 at 12:27 AM logoSangamo shares jump on Pfizer collaboration, quarterly results - May 10 at 7:25 PM logoPfizer's Q1 Shows Reasons Not To Buy This Icon - Seeking Alpha - May 10 at 11:41 AM logoPfizer Inc. (PFE) Expected to Post Earnings of $0.65 Per Share - May 10 at 8:38 AM logoFDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer - May 9 at 6:46 PM



Pfizer (PFE) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by Staff